Alvopem^® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Sharareh Seifi1 Chronic Respiratory Disease Research CenterNational Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical SciencesTehranIran

Babak Salimi1 Chronic Respiratory Disease Research CenterNational Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical SciencesTehranIran;4 Masih Daneshvari HospitalDarabad Avenue, Shahid Bahonar Roundabout1956944413TehranIran

Zahra Esfahani Monfared1 Chronic Respiratory Disease Research CenterNational Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical SciencesTehranIran

Cyrus Sabahi2 Faculty of PharmacyTehran University of Medical SciencesTehranIran

Hamidreza Kafi3 Medical DepartmentOrchid Pharmed CompanyNo 12, 70th Alley, Seyed Jamaledin Asad Abadi St., Yousef AbadTehranIran

Adnan Khosravi1 Chronic Respiratory Disease Research CenterNational Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical SciencesTehranIran;4 Masih Daneshvari HospitalDarabad Avenue, Shahid Bahonar Roundabout1956944413TehranIranCorrespondence[email protected]

https://orcid.org/0000-0003-3273-823X

Alvopem^® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Table 1 Patients’ baseline characteristics

Table 2 Incidence of AEs classified by SOC and PT

Table 3 Incidence of hematologic AEs classified by SOC and PT based on gender

Table 4 Frequency of AEs based on causality assessment

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

Figures & data

Table 1 Patients’ baseline characteristics

Table 2 Incidence of AEs classified by SOC and PT

Table 3 Incidence of hematologic AEs classified by SOC and PT based on gender

Table 4 Frequency of AEs based on causality assessment

Availability of data and materials

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Alvopem^® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance